MP29-02 provides nasal, ocular symptom relief faster than current monotherapies

Intranasal formulation of azelastine hydrochloride and fluticasone propionate appears to be timelier in alleviating nasal and ocular symptoms in patients with allergic rhinitis than current monotherapies, according to research presented at the Experimental Rhinology and Immunology of the Nose Symposium in Stockholm.

Peter W. Hellings, MD, PhD, of University Hospitals Leuven in Belgium, and colleagues conducted a randomized, double blind, placebo-controlled, 14-day, parallel-group trial on 610 patients with moderate to severe allergic rhinitis (AR) to determine the efficacy of azelastine hydrochloride (AZ) and fluticasone propionate (FP) (Dymista, Meda Pharmaceuticals) as a combination therapy.

Patients were randomized to receive either the combination therapy, one spray per nostril daily of either AZ (548 µg) alone, FP (200 µg) alone or placebo nasal spray.

Change from baseline using a seven-symptom score for nasal and ocular symptoms (rT7SS) was assessed after the trial was completed.

Overall, patients receiving MP29-02 had a greater reduction in rT7SS when compared with FP (relative difference [RD] = 52%; P = .0013) and AZ (RD = 56%; P = .0004) alone. The level of relief achieved by patients receiving MP29-02 on the second day of the trial was not achieved before the fifth day of FP alone and the eighth day of AZ alone.

Reference:

Hellings P, et al. Abstract P34. Presented at: Experimental Rhinology and Immunology of the Nose Symposium; March 19-21, 2015; Stockholm, Sweden.

Disclosure: Healio.com/Allergy was unable to determine relevant financial disclosures at the time of publication.